Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study
José Javier Morales-Núñez,1 Mariel García-Chagollán,1 José Francisco Muñoz-Valle,1 Saúl Alberto Díaz-Pérez,1 Paola Carolina Torres-Hernández,2 Saraí Citlalic Rodríguez-Reyes,3 Guillermo Santoscoy-Ascencio,4 José Julio Sierra García de Quevedo,4 Jorge Hernández-Bello1 1Institute of Re...
Saved in:
Main Authors: | Morales-Núñez JJ (Author), García-Chagollán M (Author), Muñoz-Valle JF (Author), Díaz-Pérez SA (Author), Torres-Hernández PC (Author), Rodríguez-Reyes SC (Author), Santoscoy-Ascencio G (Author), Sierra García de Quevedo JJ (Author), Hernández-Bello J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021) -
Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer-BioNTech) COVID‐19 vaccination
by: Akihiro Matsubara, et al.
Published: (2021) -
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
by: Rumiko Shimazawa, et al.
Published: (2021) -
Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
by: Xiaotian Wu, MBBS, MRCP, MMed, et al.
Published: (2022) -
Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
by: Rujittika Mungmunpuntipantip, et al.
Published: (2022)